Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-08-17

Danaher (DHR)

Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$23,795,280
Rainer Blair total, FY2025
50th
CEO pay percentile vs peers
343:1
CEO-to-median pay ratio
93.02%
Say-on-pay support, latest vote
Companies that benchmark against DHR
27 companies name DHR as a compensation peer

Each company listed discloses DHR in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named DHR in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Rainer Blair$1,400,000$0$9,292,370$8,386,657$4,194,400$0$521,853$23,795,280
President and CEO
Julie Montgomery848,00004,425,3094,294,4671,587,8800139,62311,295,279
Executive Vice President
Christopher Riley848,00004,425,3094,294,4671,587,8800100,19211,255,848
Executive Vice President
Matthew McGrew1,005,33002,519,0582,273,5371,882,4800287,1147,967,519
Executive Vice President and CFO
Jose-Carlos Gutierrez-Ramos888,46001,959,4221,768,3231,530,550097,0166,243,771
Executive Vice President

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY20242025
Rainer Blair$23,795,280$20,903,282
Julie Montgomery11,295,279
Christopher Riley11,255,848
Matthew McGrew7,967,5197,496,078
Jose-Carlos Gutierrez-Ramos6,243,7717,197,185

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
A. Shane SandersDirector2026-04-24A231.81$177$41,088Derivative, Class A CommonForm 4 ↗
Alan G. SpoonDirector2026-04-24A252.3217744,724Derivative, Class A CommonForm 4 ↗
Raymond C. StevensDirector2026-04-24A199.2617735,319Derivative, Class A CommonForm 4 ↗
Elias A. Zerhouni, MDDirector2026-04-24A259.7217746,035Derivative, Class A CommonForm 4 ↗
Dividend-equivalent accruals2026-04-2437~6,6242 insiders, 2 accrual rows
Feroz DewanDirector2026-04-24A187.8917733,304Derivative, Class A CommonForm 4 ↗
Alan G. SpoonDirector2026-05-01D3,29800Derivative, Class A CommonForm 4 ↗
Alan G. SpoonDirector2026-05-01D1,358175237,207CommonForm 4 ↗
Alan G. SpoonDirector2026-05-01A3,29872237,060CommonForm 4 ↗
Dividend-equivalent accruals2026-05-1513,5928 insiders, 8 accrual rows
Elias A. Zerhouni, MDDirector2026-05-15A68000CommonForm 4 ↗
Raymond C. StevensDirector2026-05-15A68000CommonForm 4 ↗
Teri L. ListDirector2026-05-15A68000CommonForm 4 ↗
Linda FillerDirector2026-05-15A68000CommonForm 4 ↗
Alan G. SpoonDirector2026-05-15A68000CommonForm 4 ↗
Charles W. LamannaDirector2026-05-15A68000CommonForm 4 ↗
A. Shane SandersDirector2026-05-15A68000CommonForm 4 ↗
Georgeann CoucharaSVP, Human Resources2026-05-15D28116245,497CommonForm 4 ↗
Feroz DewanDirector2026-05-15A68000CommonForm 4 ↗
Elias A. Zerhouni, MDDirector2026-07-15A3,29872237,060CommonForm 4 ↗
Elias A. Zerhouni, MDDirector2026-07-15D3,29800Derivative, Class A CommonForm 4 ↗
Linda FillerDirector2026-07-15D1,181201237,133CommonForm 4 ↗
Linda FillerDirector2026-07-15D3,29800Derivative, Class A CommonForm 4 ↗
Elias A. Zerhouni, MDDirector2026-07-15D1,181201237,133CommonForm 4 ↗
Linda FillerDirector2026-07-15A3,29872237,060CommonForm 4 ↗
Christopher BoudaVP, Chief Accounting Officer2026-07-15D6020112,047CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

View all 34 transactions
InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
A. Shane SandersDirector2026-04-24A231.81$177$41,088Derivative, Class A CommonForm 4 ↗
Alan G. SpoonDirector2026-04-24A252.3217744,724Derivative, Class A CommonForm 4 ↗
Raymond C. StevensDirector2026-04-24A199.2617735,319Derivative, Class A CommonForm 4 ↗
Elias A. Zerhouni, MDDirector2026-04-24A259.7217746,035Derivative, Class A CommonForm 4 ↗
Linda FillerDirector2026-04-24A20.121773,566Derivative, Class A CommonForm 4 ↗
Feroz DewanDirector2026-04-24A187.8917733,304Derivative, Class A CommonForm 4 ↗
Teri L. ListDirector2026-04-24A17.251773,057Derivative, Class A CommonForm 4 ↗
Alan G. SpoonDirector2026-05-01D3,29800Derivative, Class A CommonForm 4 ↗
Alan G. SpoonDirector2026-05-01D1,358175237,207CommonForm 4 ↗
Alan G. SpoonDirector2026-05-01A3,29872237,060CommonForm 4 ↗
Alan G. SpoonDirector2026-05-15A1,69900Derivative, Class A CommonForm 4 ↗
A. Shane SandersDirector2026-05-15A1,69900Derivative, Class A CommonForm 4 ↗
Feroz DewanDirector2026-05-15A1,69900Derivative, Class A CommonForm 4 ↗
Elias A. Zerhouni, MDDirector2026-05-15A68000CommonForm 4 ↗
Raymond C. StevensDirector2026-05-15A68000CommonForm 4 ↗
Teri L. ListDirector2026-05-15A68000CommonForm 4 ↗
Teri L. ListDirector2026-05-15A1,69900Derivative, Class A CommonForm 4 ↗
Charles W. LamannaDirector2026-05-15A1,69900Derivative, Class A CommonForm 4 ↗
Linda FillerDirector2026-05-15A68000CommonForm 4 ↗
Alan G. SpoonDirector2026-05-15A68000CommonForm 4 ↗
Charles W. LamannaDirector2026-05-15A68000CommonForm 4 ↗
A. Shane SandersDirector2026-05-15A68000CommonForm 4 ↗
Linda FillerDirector2026-05-15A1,69900Derivative, Class A CommonForm 4 ↗
Georgeann CoucharaSVP, Human Resources2026-05-15D28116245,497CommonForm 4 ↗
Raymond C. StevensDirector2026-05-15A1,69900Derivative, Class A CommonForm 4 ↗
Elias A. Zerhouni, MDDirector2026-05-15A1,69900Derivative, Class A CommonForm 4 ↗
Feroz DewanDirector2026-05-15A68000CommonForm 4 ↗
Elias A. Zerhouni, MDDirector2026-07-15A3,29872237,060CommonForm 4 ↗
Elias A. Zerhouni, MDDirector2026-07-15D3,29800Derivative, Class A CommonForm 4 ↗
Linda FillerDirector2026-07-15D1,181201237,133CommonForm 4 ↗
Linda FillerDirector2026-07-15D3,29800Derivative, Class A CommonForm 4 ↗
Elias A. Zerhouni, MDDirector2026-07-15D1,181201237,133CommonForm 4 ↗
Linda FillerDirector2026-07-15A3,29872237,060CommonForm 4 ↗
Christopher BoudaVP, Chief Accounting Officer2026-07-15D6020112,047CommonForm 4 ↗
03

Grants of plan-based awards — fiscal year 2025

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Christopher RileyRSU2025-03-0112,034$2,465,887
Christopher RileyOPTION2025-03-0134,3812,526,144
Christopher RileyPSU2025-03-012,1068,42416,8481,959,422
Rainer BlairOPTION2025-03-01114,1438,386,657
Matthew McGrewOPTION2025-03-0130,9432,273,537
Matthew McGrewPSU2025-03-012,70810,83021,6602,519,058
Julie MontgomeryOPTION2025-03-0134,3812,526,144
Jose-Carlos Gutierrez-RamosPSU2025-03-012,1068,42416,8481,959,422
Julie MontgomeryPSU2025-03-012,1068,42416,8481,959,422
Julie MontgomeryRSU2025-03-0112,0342,465,887
Julie MontgomeryOPTION2025-03-0124,0671,768,323
Rainer BlairPSU2025-03-019,98839,95079,9009,292,370
Jose-Carlos Gutierrez-RamosOPTION2025-03-0124,0671,768,323
Christopher RileyOPTION2025-03-0124,0671,768,323
03b

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Christopher Riley$2,465,887$1,959,422$4,294,46722.5%
Rainer Blair09,292,3708,386,65752.6%
Matthew McGrew02,519,0582,273,53752.6%
Julie Montgomery2,465,8871,959,4224,294,46722.5%
Jose-Carlos Gutierrez-Ramos01,959,4221,768,32352.6%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Rainer BlairRSU7,817$1,807,800
Christopher RileyRSU778178,100
Jose-Carlos Gutierrez-RamosRSU1,695393,799
Rainer BlairRSU8,4741,968,590
Julie MontgomeryRSU16,8483,878,410
Julie MontgomeryOption1,482241.22
Julie MontgomeryRSU478109,653
Jose-Carlos Gutierrez-RamosOption18,320221.29
Jose-Carlos Gutierrez-RamosRSU1,710395,489
Rainer BlairRSU7,8171,807,800
Matthew McGrewRSU2,684623,458
Christopher RileyRSU1,222282,509
Julie MontgomeryOption1,486198.09
Jose-Carlos Gutierrez-RamosOption7,107241.22
Julie MontgomeryRSU40,811
Christopher RileyOption250,140
Matthew McGrewPSU86,424
Jose-Carlos Gutierrez-RamosOption106,927
Christopher RileyRSU1,046242,901
Rainer BlairOption91,602221.29
Matthew McGrewRSU21,6604,986,132
Christopher RileyRSU12,0342,754,823
Julie MontgomeryRSU848196,900
Jose-Carlos Gutierrez-RamosOption16,285255.87
Julie MontgomeryOption5,235255.87
Julie MontgomeryRSU519119,267
Jose-Carlos Gutierrez-RamosRSU2,260517,588
Julie MontgomeryRSU733169,528
Christopher RileyRSU1,222282,509
Rainer BlairRSU19,9004,622,957
Matthew McGrewRSU2,199508,469
Christopher RileyRSU778178,100
Matthew McGrewOption13,920198.09
Rainer BlairOption46,405198.09
Christopher RileyOption2,517241.22
Christopher RileyOption2,221241.22
Christopher RileyRSU16,8483,878,410
Christopher RileyOption5,650221.29
Christopher RileyOption3,715198.09
Julie MontgomeryRSU12,0342,754,823
Jose-Carlos Gutierrez-RamosRSU16,8483,878,410
Jose-Carlos Gutierrez-RamosRSU2,199503,395
Rainer BlairOption114,143207.76
Rainer BlairOption74,443255.87
Matthew McGrewOption30,943207.76
Matthew McGrewOption20,937255.87
Matthew McGrewOption29,007221.29
Christopher RileyOption34,381207.76
Christopher RileyOption24,067207.76
Christopher RileyOption11,632255.87
Rainer BlairPSU252,473
Christopher RileyRSU48,189
Julie MontgomeryOption1,272240.13
Julie MontgomeryPSU14,746
Rainer BlairRSU103,774
Jose-Carlos Gutierrez-RamosOption5,235255.87
Julie MontgomeryOption24,067207.76
Rainer BlairOption919,887
Jose-Carlos Gutierrez-RamosOption6,107221.29
Matthew McGrewOption445,427
Julie MontgomeryOption147,841
Jose-Carlos Gutierrez-RamosOption4,951198.09
Christopher RileyPSU28,843
Jose-Carlos Gutierrez-RamosPSU25,199
Jose-Carlos Gutierrez-RamosRSU12,807
Julie MontgomeryOption4,582221.29
Matthew McGrewRSU66,641
Christopher RileyRSU16,8483,878,410
Rainer BlairRSU19,90018,392,980
Matthew McGrewOption12,585241.22
Matthew McGrewRSU21,6604,986,132
Matthew McGrewRSU2,684623,458
Christopher RileyRSU12,0342,754,823
Christopher RileyRSU1,046242,901
Rainer BlairOption41,457241.22
Rainer BlairRSU8,4741,968,590
Matthew McGrewRSU2,199508,469
05

Incentive-plan design — the Compensation Discussion & Analysis

Compensation should fairly pay directors for work required in a company of our size and scope, and differentiate among directors where appropriate to reflect different levels of responsibilities; a significant portion should be stock-based to align with long-term shareholder interests.

CEO STI target (% of salary)
CEO LTI target (% of salary)
Independent consultantFW Cook
Clawback policytrue
Anti-hedgingtrue
Anti-pledgingTrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-05-05553,754,51941,555,863473,27493.02%Passed
20252025-05-06562,800,46130,795,3422,887,98794.81%Passed
20242024-05-07586,649,11841,950,4642,206,70193.33%Passed
20232023-05-09587,524,84731,456,0911,576,63094.92%Passed
20222022-05-10561,170,14635,745,911959,98894.01%Passed
20212021-05-05575,840,38528,142,2561,462,91695.34%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20262026-05-0593.02%a
20252025-05-0694.81%b
20242024-05-0793.33%c

a. Voting standard not stated in the filing.

b. Voting standard not stated in the filing.

c. Voting standard not stated in the filing.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

07

CEO pay ratio

Ratio (CEO : median employee)343 : 1
CEO total compensation$23,795,280
Median employee compensation$69,440
08

Director compensation — fiscal year 2025

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Linda FillerIndependent · Lead Independent Director · Nominating & Governance (Chair) · Science & Technology$192,500$110,178$110,856$0$0$413,534
Teri L. ListIndependent · Audit · Compensation (Chair)158,500110,178110,85600379,534
A. Shane SandersIndependent · Audit (Chair) · Nominating & Governance267,678110,85600378,534
Charles W. LamannaIndependent · Science & Technology · Newly elected111,150131,370132,16400374,684
Elias A. Zerhouni, MDIndependent · Nominating & Governance · Science & Technology (Chair)262,678110,85600373,534
Raymond C. Stevens, Ph.DIndependent · Audit · Science & Technology240,178110,85600351,034
Feroz DewanIndependent · Compensation · Nominating & Governance · Science & Technology240,178110,85600351,034
John T. SchwietersIndependent · Audit · Nominating & Governance130,000110,178110,85600351,034
Alan G. SpoonIndependent · Compensation240,178110,85600351,034
Jessica L. Mega, MD, MPHIndependent · Departed during FY130,000110,178110,85600351,034
Rainer M. BlairEmployee director · Executive · Finance · Science & Technology00000
Steven M. RalesEmployee director · Board Chair · Executive · Finance · Science & Technology00000
Mitchell P. RalesEmployee director · Executive (Chair) · Finance (Chair)00000
09

Board fee structure and ownership guideline

Annual cash retainer
Annual equity retainer
Per board meeting fee
Committee chair fees (audit / comp / nom-gov)30,000
Stock ownership guideline
09b

Total cost of the board

ComponentFY2025
Cash retainers and fees$722,150
Equity awards (grant-date value)$1,822,972
All other compensation$0
Total cost of the board$2,545,122

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10

Disclosed peer group — fiscal year 2025

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

10a

Peer reciprocity

Of the companies Danaher names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.

Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Danaher.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Thermo Fisher Scientific Inc.2025Marc Casper$1,785,534$65,730,211$7,951,377$3,742,123$79,923,350
2Eli Lilly and Company2025David Ricks1,700,00023,325,00006,485,50036,698,337
3Johnson & Johnson2025Joaquin Duato1,600,00015,028,9485,927,9954,298,70032,758,111
4AbbVie Inc.2025Robert Michael1,700,00013,268,4563,199,1545,200,00032,530,984
5Gilead Sciences2025Daniel O'Day1,795,19215,238,4024,500,0604,848,12028,437,198
6IQVIA Holdings Inc.2025Ari Bousbib1,800,00015,749,9574,528,3174,966,12728,128,245
7Amgen Inc.2025Robert Bradway1,925,40912,599,5895,399,9963,907,00024,693,120
8Danaher2025Rainer Blair1,400,0009,292,3708,386,6574,194,40023,795,280
9Boston Scientific Corporation2025Michael Mahoney1,442,60313,608,0563,749,9804,002,00123,532,050
10Medtronic Inc.2026Geoffrey Martha1,399,03913,672,2005,175,5592,307,20022,940,252
11Bristol-Myers Squibb Company2025Christopher Boerner1,586,34616,061,39903,754,68421,879,919
12Stryker Corporation2025Kevin Lobo1,500,00016,684,91702,250,00021,401,495
13Merck & Co.2025Robert Davis1,645,30212,102,8383,380,0042,326,50020,797,845
14Becton Dickinson & Co.2025Thomas Polen1,395,4639,991,8543,311,8611,852,01017,129,140
15Agilent Technologies2025Padraig McDonnell1,141,3458,169,8502,017,7591,436,80912,827,236

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10c

Incentive design against the same peers

CompanyAnnual incentive payoutLong-term vehicle mixPSU measures include TSRCompensation consultant
Danahernot disclosedOptions 50 · RSU 50not disclosedFW Cook
AbbVie Inc.not disclosedPSU 40 · RSU 40 · Options 20Yes — Relative TSRSemler Brossy
Agilent Technologiesnot disclosedPSU 60 · Options 20 · RSU 20NoSemler Brossy
Amgen Inc.136.0%PSU 50 · Options 30 · RSU 20Yes — relative TSRFrederic W. Cook & Co., Inc. (FW Cook)
Becton Dickinson & Co.85%PSU 50 · Options 25 · RSU 25NoSemler Brossy
Boston Scientific Corporation173%PSU 50 · RSU 25 · Options 25NoSemler Brossy Consulting Group, LLC
Bristol-Myers Squibb Company157.66%PSU 60 · MSU 40Yes — 3-Year Relative TSR CAGRFarient Advisors LLC
Eli Lilly and Company218%PSU 100NoFW Cook
Gilead Sciences180%PSU 50 · Options 25 · RSU 25Yes — Relative TSRFW Cook
IQVIA Holdings Inc.not disclosedPSU 75 · Options 25YesMeridian Compensation Partners, LLC
Johnson & Johnsonnot disclosednot disclosednot disclosedSemler Brossy Consulting Group
Medtronic Inc.103%PSU 50 · Options 30 · RSU 20NoSemler Brossy
Merck & Co.94%PSU 60 · RSU 20 · Options 20Yes — Relative Total Shareholder Return (R-TSR)FW Cook
Stryker Corporation100%PSU 48 · Options 34NoSemler Brossy
Thermo Fisher Scientific Inc.99.8%PSU 50 · Options 50Yes — Relative TSRPearl Meyer

Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Rainer BlairDEF 14A2026-03-250000313616-26-000101Section “2025 Summary Compensation Table” · page 52. As printed: 23,795,280. Filing ↗machine: t122 · r2 · c21 · span 1070180–1070190
2Section 01, Julie MontgomeryDEF 14A2026-03-250000313616-26-000101Section “2025 Summary Compensation Table” · page 52. As printed: 11,295,279. Filing ↗machine: t23 · r14 · c21 · span 285933–285943
3Section 01, Christopher RileyDEF 14A2026-03-250000313616-26-000101Section “2025 Summary Compensation Table” · page 52. As printed: 11,255,848. Filing ↗machine: t23 · r12 · c21 · span 280628–280638
4Section 01, Matthew McGrewDEF 14A2026-03-250000313616-26-000101Section “2025 Summary Compensation Table” · page 52. As printed: 7,967,519. Filing ↗machine: t122 · r5 · c21 · span 1082694–1082703
5Section 01, Jose-Carlos Gutierrez-RamosDEF 14A2026-03-250000313616-26-000101Section “2025 Summary Compensation Table” · page 52. As printed: 6,243,771. Filing ↗machine: t122 · r10 · c21 · span 1105232–1105241
6Section 03, Christopher Riley RSUDEF 14A2026-03-250000313616-26-000101Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t129 · r12 · c12 · span 1242737–1242746
7Section 03, Christopher Riley OPTIONDEF 14A2026-03-250000313616-26-000101Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t129 · r11 · c12 · span 1239486–1239495
8Section 03, Christopher Riley PSUDEF 14A0000313616-26-000101Section “ERRED TO AS THE NAMED EXECUTIVE OFFICERS, OR NEOS. THE CONTENT OF THIS COMPENSATION DISCUSSION AND ANALYSIS IS ORGANIZED IN” · grants of plan-based awards table. Filing ↗machine: t131 · r40 · c12 · span 1445681–1445687
9Section 03, Rainer Blair OPTIONDEF 14A2026-03-250000313616-26-000101Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t23 · r8 · c10 · span 267909–267918
10Section 03, Matthew McGrew OPTIONDEF 14A2026-03-250000313616-26-000101Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t23 · r10 · c10 · span 273376–273385
11Section 03, Matthew McGrew PSUDEF 14A2026-03-250000313616-26-000101Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t23 · r10 · c7 · span 272839–272848
12Section 03, Julie Montgomery OPTIONDEF 14A2026-03-250000313616-26-000101Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t129 · r16 · c12 · span 1257281–1257290
13Section 03, Jose-Carlos Gutierrez-Ramos PSUDEF 14A2026-03-250000313616-26-000101Section “CFO C” · grants of plan-based awards table. Filing ↗machine: t23 · r16 · c7 · span 288988–288997
14Section 03, Julie Montgomery PSUDEF 14A0000313616-26-000101Section “ERRED TO AS THE NAMED EXECUTIVE OFFICERS, OR NEOS. THE CONTENT OF THIS COMPENSATION DISCUSSION AND ANALYSIS IS ORGANIZED IN” · grants of plan-based awards table. Filing ↗machine: t133 · r16 · c12 · span 1528470–1528476
15Section 03, Julie Montgomery RSUDEF 14A2026-03-250000313616-26-000101Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t129 · r17 · c12 · span 1260939–1260948
16Section 03, Julie Montgomery OPTIONDEF 14A2026-03-250000313616-26-000101Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t129 · r15 · c12 · span 1253648–1253657
17Section 03, Rainer Blair PSUDEF 14A2026-03-250000313616-26-000101Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t23 · r8 · c7 · span 267354–267363
18Section 03, Jose-Carlos Gutierrez-Ramos OPTIONDEF 14A2026-03-250000313616-26-000101Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t23 · r16 · c10 · span 289450–289459
19Section 03, Christopher Riley OPTIONDEF 14A2026-03-250000313616-26-000101Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t129 · r10 · c10 · span 1235733–1235739
20Section 07, pay ratioDEF 14A2026-03-250000313616-26-000101Section “CEO Pay Ratio”. As printed: 343 : 1. Filing ↗machine: span 1826227–1826230
21Section 08, Linda FillerDEF 14A2026-03-250000313616-26-000101Section “Director Compensation”. As printed: 413,534. Filing ↗machine: t76 · r3 · c7 · span 667887–667894
22Section 08, Teri L. ListDEF 14A2026-03-250000313616-26-000101Section “Director Compensation”. As printed: 379,534. Filing ↗machine: t76 · r5 · c7 · span 672214–672221
23Section 08, A. Shane SandersDEF 14A2026-03-250000313616-26-000101Section “Director Compensation”. As printed: 378,534. Filing ↗machine: t76 · r7 · c7 · span 676759–676766
24Section 08, Charles W. LamannaDEF 14A2026-03-250000313616-26-000101Section “Director Compensation”. As printed: 374,684. Filing ↗machine: t76 · r4 · c7 · span 670060–670067
25Section 08, Elias A. Zerhouni, MDDEF 14A2026-03-250000313616-26-000101Section “Director Compensation”. As printed: 373,534. Filing ↗machine: t76 · r11 · c7 · span 685618–685625
26Section 08, Raymond C. Stevens, Ph.DDEF 14A2026-03-250000313616-26-000101Section “Director Compensation”. As printed: 351,034. Filing ↗machine: t76 · r10 · c7 · span 683267–683274
27Section 08, Feroz DewanDEF 14A2026-03-250000313616-26-000101Section “Director Compensation”. As printed: 351,034. Filing ↗machine: t76 · r2 · c7 · span 665702–665709
28Section 08, John T. SchwietersDEF 14A2026-03-250000313616-26-000101Section “Director Compensation”. As printed: 351,034. Filing ↗machine: t76 · r8 · c7 · span 678744–678751
29Section 08, Alan G. SpoonDEF 14A2026-03-250000313616-26-000101Section “Director Compensation”. As printed: 351,034. Filing ↗machine: t76 · r9 · c7 · span 681087–681094
30Section 08, Jessica L. Mega, MD, MPHDEF 14A2026-03-250000313616-26-000101Section “Director Compensation”. As printed: 351,034. Filing ↗machine: t76 · r6 · c7 · span 674413–674420
31Section 08, Rainer M. BlairDEF 14A2026-03-250000313616-26-000101Section “Director Compensation”. As printed: 0. Filing ↗
32Section 08, Steven M. RalesDEF 14A2026-03-250000313616-26-000101Section “Director Compensation”. As printed: 0. Filing ↗
33Section 08, Mitchell P. RalesDEF 14A2026-03-250000313616-26-000101Section “Director Compensation”. As printed: 0. Filing ↗
34Section 02, A. Shane Sanders 2026-04-24Form 42026-04-280000313616-26-000122Insider equity transaction reported since the proxy statement. Filing ↗
35Section 02, Alan G. Spoon 2026-04-24Form 42026-04-280000313616-26-000118Insider equity transaction reported since the proxy statement. Filing ↗
36Section 02, Raymond C. Stevens 2026-04-24Form 42026-04-280000313616-26-000123Insider equity transaction reported since the proxy statement. Filing ↗
37Section 02, Elias A. Zerhouni, MD 2026-04-24Form 42026-04-280000313616-26-000120Insider equity transaction reported since the proxy statement. Filing ↗
38Section 02, Linda Filler 2026-04-24Form 42026-04-280000313616-26-000119Insider equity transaction reported since the proxy statement. Filing ↗
39Section 02, Feroz Dewan 2026-04-24Form 42026-04-280000313616-26-000117Insider equity transaction reported since the proxy statement. Filing ↗
40Section 02, Teri L. List 2026-04-24Form 42026-04-280000313616-26-000121Insider equity transaction reported since the proxy statement. Filing ↗
41Section 02, Alan G. Spoon 2026-05-01Form 42026-05-040000313616-26-000125Insider equity transaction reported since the proxy statement. Filing ↗
42Section 02, Alan G. Spoon 2026-05-01Form 42026-05-040000313616-26-000125Insider equity transaction reported since the proxy statement. Filing ↗
43Section 02, Alan G. Spoon 2026-05-01Form 42026-05-040000313616-26-000125Insider equity transaction reported since the proxy statement. Filing ↗
44Section 02, Alan G. Spoon 2026-05-15Form 42026-05-190000313616-26-000144Insider equity transaction reported since the proxy statement. Filing ↗
45Section 02, A. Shane Sanders 2026-05-15Form 42026-05-190000313616-26-000143Insider equity transaction reported since the proxy statement. Filing ↗
46Section 02, Feroz Dewan 2026-05-15Form 42026-05-190000313616-26-000140Insider equity transaction reported since the proxy statement. Filing ↗
47Section 02, Elias A. Zerhouni, MD 2026-05-15Form 42026-05-190000313616-26-000141Insider equity transaction reported since the proxy statement. Filing ↗
48Section 02, Raymond C. Stevens 2026-05-15Form 42026-05-190000313616-26-000145Insider equity transaction reported since the proxy statement. Filing ↗
49Section 02, Teri L. List 2026-05-15Form 42026-05-190000313616-26-000142Insider equity transaction reported since the proxy statement. Filing ↗
50Section 02, Teri L. List 2026-05-15Form 42026-05-190000313616-26-000142Insider equity transaction reported since the proxy statement. Filing ↗
51Section 02, Charles W. Lamanna 2026-05-15Form 42026-05-190000313616-26-000139Insider equity transaction reported since the proxy statement. Filing ↗
52Section 02, Linda Filler 2026-05-15Form 42026-05-190000313616-26-000147Insider equity transaction reported since the proxy statement. Filing ↗
53Section 02, Alan G. Spoon 2026-05-15Form 42026-05-190000313616-26-000144Insider equity transaction reported since the proxy statement. Filing ↗
54Section 02, Charles W. Lamanna 2026-05-15Form 42026-05-190000313616-26-000139Insider equity transaction reported since the proxy statement. Filing ↗
55Section 02, A. Shane Sanders 2026-05-15Form 42026-05-190000313616-26-000143Insider equity transaction reported since the proxy statement. Filing ↗
56Section 02, Linda Filler 2026-05-15Form 42026-05-190000313616-26-000147Insider equity transaction reported since the proxy statement. Filing ↗
57Section 02, Georgeann Couchara 2026-05-15Form 42026-05-190000313616-26-000146Insider equity transaction reported since the proxy statement. Filing ↗
58Section 02, Raymond C. Stevens 2026-05-15Form 42026-05-190000313616-26-000145Insider equity transaction reported since the proxy statement. Filing ↗
59Section 02, Elias A. Zerhouni, MD 2026-05-15Form 42026-05-190000313616-26-000141Insider equity transaction reported since the proxy statement. Filing ↗
60Section 02, Feroz Dewan 2026-05-15Form 42026-05-190000313616-26-000140Insider equity transaction reported since the proxy statement. Filing ↗
61Section 02, Elias A. Zerhouni, MD 2026-07-15Form 42026-07-160000313616-26-000157Insider equity transaction reported since the proxy statement. Filing ↗
62Section 02, Elias A. Zerhouni, MD 2026-07-15Form 42026-07-160000313616-26-000157Insider equity transaction reported since the proxy statement. Filing ↗
63Section 02, Linda Filler 2026-07-15Form 42026-07-160000313616-26-000158Insider equity transaction reported since the proxy statement. Filing ↗
64Section 02, Linda Filler 2026-07-15Form 42026-07-160000313616-26-000158Insider equity transaction reported since the proxy statement. Filing ↗
65Section 02, Elias A. Zerhouni, MD 2026-07-15Form 42026-07-160000313616-26-000157Insider equity transaction reported since the proxy statement. Filing ↗
66Section 02, Linda Filler 2026-07-15Form 42026-07-160000313616-26-000158Insider equity transaction reported since the proxy statement. Filing ↗
67Section 02, Christopher Bouda 2026-07-15Form 42026-07-160000313616-26-000159Insider equity transaction reported since the proxy statement. Filing ↗
68Section 06, 2026 voteForm 8-K2026-05-070000313616-26-000127Item 5.07 · say-on-pay result. As reported: 93.02% (votes for as printed: 553,754,519). Filing ↗
69Section 06, 2025 voteForm 8-K2025-05-080000313616-25-000110Item 5.07 · say-on-pay result. As reported: 94.81% (votes for as printed: 562,800,461). Filing ↗
70Section 06, 2024 voteForm 8-K2024-05-090000313616-24-000133Item 5.07 · say-on-pay result. As reported: 93.33% (votes for as printed: 586,649,118). Filing ↗
71Section 03b vehicle mix (computed)ComputedcomputedRSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio
72Section 09b board cost (computed)ComputedcomputedCash 722,150 + equity 1,822,972 + all other 0 = 2,545,122, summed across the director compensation table rows.machine: formula: Σ = 2,545,122
73Thermo Fisher Scientific Inc., Section 10b CEO totalDEF 14A2026-04-070001193125-26-144585CEO total compensation as printed in Thermo Fisher Scientific Inc.'s own proxy. As printed: 79,923,350. Filing ↗machine: span 973487–973497
74Eli Lilly and Company, Section 10b CEO totalDEF 14A2026-03-200000059478-26-000029CEO total compensation as printed in Eli Lilly and Company's own proxy. As printed: 36,698,337. Filing ↗machine: t92 · r2 · c20 · span 925013–925024
75Johnson & Johnson, Section 10b CEO totalDEF 14A2026-03-110000200406-26-000063CEO total compensation as printed in Johnson & Johnson's own proxy. As printed: 32,758,111. Filing ↗machine: r3 · c27 · span 1621235–1621246
76AbbVie Inc., Section 10b CEO totalDEF 14A2026-03-230001104659-26-033387CEO total compensation as printed in AbbVie Inc.'s own proxy. As printed: 32,530,984. Filing ↗machine: t210 · r9 · c26 · span 1414083–1414093
77Gilead Sciences, Section 10b CEO totalDEF 14A2026-03-200001308179-26-000106CEO total compensation as printed in Gilead Sciences's own proxy. As printed: 28,437,198. Filing ↗machine: t414 · r1 · c29 · span 989582–989592
78IQVIA Holdings Inc., Section 10b CEO totalDEF 14A2026-02-270001628280-26-012892CEO total compensation as printed in IQVIA Holdings Inc.'s own proxy. As printed: 28,128,245. Filing ↗machine: t232 · r4 · c10 · span 1613956–1613966
79Amgen Inc., Section 10b CEO totalDEF 14A2026-04-070001193125-26-145588CEO total compensation as printed in Amgen Inc.'s own proxy. As printed: 24,693,120. Filing ↗machine: span 1591156–1591166
80Danaher (subject), Section 10b CEO totalDEF 14A2026-03-250000313616-26-000101CEO total compensation as printed in Danaher's own proxy. As printed: 23,795,280. Filing ↗machine: t122 · r2 · c21 · span 1070180–1070190
81Boston Scientific Corporation, Section 10b CEO totalDEF 14A2026-03-180000885725-26-000025CEO total compensation as printed in Boston Scientific Corporation's own proxy. As printed: 23,532,050. Filing ↗machine: r2 · c27 · span 1249807–1249817
82Medtronic Inc., Section 10b CEO totalDEF 14A2026-08-170001613103-26-000010CEO total compensation as printed in Medtronic Inc.'s own proxy. As printed: 22,940,252. Filing ↗machine: span 988220–988230
83Bristol-Myers Squibb Company, Section 10b CEO totalDEF 14A2026-03-250000014272-26-000006CEO total compensation as printed in Bristol-Myers Squibb Company's own proxy. As printed: 21,879,919. Filing ↗machine: t168 · r3 · c15 · span 1302160–1302170
84Stryker Corporation, Section 10b CEO totalDEF 14A2026-03-230000310764-26-000013CEO total compensation as printed in Stryker Corporation's own proxy. As printed: 21,401,495. Filing ↗machine: t101 · r2 · c7 · span 1584979–1584989
85Merck & Co., Section 10b CEO totalDEF 14A2026-04-080001193125-26-147704CEO total compensation as printed in Merck & Co.'s own proxy. As printed: 20,797,845. Filing ↗machine: span 1371012–1371022
86Becton Dickinson & Co., Section 10b CEO totalDEF 14A2025-12-180001628280-25-057846CEO total compensation as printed in Becton Dickinson & Co.'s own proxy. As printed: 17,129,140. Filing ↗machine: r2 · c27 · span 1173285–1173295
87Agilent Technologies, Section 10b CEO totalDEF 14A2026-02-060001193125-26-040286CEO total compensation as printed in Agilent Technologies's own proxy. As printed: 12,827,236. Filing ↗machine: r3 · c29 · span 1450982–1450992
88Section 10a, AbbVie Inc. reciprocityDEF 14A0001104659-26-033387AbbVie Inc.'s most recent proxy was read; its disclosed peer group does not include Danaher. Filing ↗
89Section 10a, Agilent Technologies reciprocityDEF 14A0001193125-26-040286Agilent Technologies names Danaher in its own disclosed peer group (read from its most recent proxy). Filing ↗
90Section 10a, Amgen Inc. reciprocityDEF 14A0001193125-26-145588Amgen Inc.'s most recent proxy was read; its disclosed peer group does not include Danaher. Filing ↗
91Section 10a, IQVIA Holdings Inc. reciprocityDEF 14A0001628280-26-012892IQVIA Holdings Inc. names Danaher in its own disclosed peer group (read from its most recent proxy). Filing ↗
92Section 10a, Gilead Sciences reciprocityDEF 14A0001308179-26-000106Gilead Sciences's most recent proxy was read; its disclosed peer group does not include Danaher. Filing ↗
93Section 10a, Bristol-Myers Squibb Company reciprocityDEF 14A0000014272-26-000006Bristol-Myers Squibb Company's most recent proxy was read; its disclosed peer group does not include Danaher. Filing ↗
94Section 10a, Merck & Co. reciprocityDEF 14A0001193125-26-147704Merck & Co.'s most recent proxy was read; its disclosed peer group does not include Danaher. Filing ↗
95Section 10a, Becton Dickinson & Co. reciprocityDEF 14A0001628280-25-057846Becton Dickinson & Co. names Danaher in its own disclosed peer group (read from its most recent proxy). Filing ↗
96Section 10a, Johnson & Johnson reciprocityDEF 14A0000200406-26-000063Johnson & Johnson's most recent proxy was read; its disclosed peer group does not include Danaher. Filing ↗
97Section 10a, Boston Scientific Corporation reciprocityDEF 14A0000885725-26-000025Boston Scientific Corporation names Danaher in its own disclosed peer group (read from its most recent proxy). Filing ↗
98Section 10a, Stryker Corporation reciprocityDEF 14A0000310764-26-000013Stryker Corporation names Danaher in its own disclosed peer group (read from its most recent proxy). Filing ↗
99Section 10a, Eli Lilly and Company reciprocityDEF 14A0000059478-26-000029Eli Lilly and Company names Danaher in its own disclosed peer group (read from its most recent proxy). Filing ↗